Clinical trial
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV…
NCT00072072 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00072072 |
|---|---|
| Title | Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase I Trial Of A COX-2 Inhibitor (Celecoxib) In Combination With An EGFR Inhibitor (OSI-774) In Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | celecoxib, erlotinib hydrochloride |
| Start date | Aug 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Nov 6, 2003 |
| Last update posted | Sep 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: